Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Bio Products Laboratory |
---|---|
Information provided by: | Bio Products Laboratory |
ClinicalTrials.gov Identifier: | NCT00504075 |
The primary objective is to determine if BPL's GAMMAPLEX raises the platelet count of subjects with chronic ITP to a threshold of 50 x 109/L, similar to that of a historical control. The secondary objectives are: 1) to determine the safety of GAMMAPLEX at the dosage used in this study. 2) to determine if GAMMAPLEX maintains platelet counts of ³ 50 x 109/L in subjects with chronic ITP for a period of time similar to that of a historical control.
Condition | Intervention | Phase |
---|---|---|
Chronic Idiopathic Thrombocytopenic Purpura |
Biological: Gammaplex, intravenous immunoglobulin Biological: Gammaplex |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase III, Multicenter, Open-Label Study To Evaluate the Efficacy and Safety of GAMMAPLEX® in Chronic Idiopathic Thrombocytopenic Purpura |
Estimated Enrollment: | 31 |
Study Start Date: | August 2007 |
Estimated Study Completion Date: | May 2010 |
Estimated Primary Completion Date: | May 2010 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 6 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Florida | |
Mid Florida Hematology & Oncology | Recruiting |
Orange City, Florida, United States, 32763 | |
Contact: Sandy Davis 386-566-3303 swarrington@auafl.com | |
Principal Investigator: Gregory Ortega, MD | |
United States, Maryland | |
Center for Cancer & Blood Disorders | Active, not recruiting |
Bethesda, Maryland, United States, 20817 | |
United States, New York | |
New York Hospital / Cornell University, Division of Pediatrics | Recruiting |
New York, New York, United States, 10021 | |
Contact: Jared Levan 212-746-3423 jal2029@med.cornell.edu | |
Principal Investigator: James B Bussel, MD | |
Department of Pediatrics, SUNY at Stony Brook | Active, not recruiting |
Stony Brook, New York, United States, 11794-8111 | |
United States, Oregon | |
Oregon Health & Science University | Recruiting |
Portland, Oregon, United States, 97239 | |
Contact: Jenifer Borruel Rector, RN BSN CCRC 503-494-7187 borruelr@ohsu.edu | |
Principal Investigator: Lynn Boshkov, MD |
Principal Investigator: | James B Bussel, MD | New York Presbyterian Hospital |
Responsible Party: | New York Presbyterian Hospital ( James B Bussel, Principal Investigator ) |
Study ID Numbers: | GMX02 |
Study First Received: | July 18, 2007 |
Last Updated: | July 17, 2009 |
ClinicalTrials.gov Identifier: | NCT00504075 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Idiopathic Thrombocytopenic Purpura Bleeding disorders Immune System and Disorders |
Purpura Autoimmune Diseases Immunologic Factors Hematologic Diseases Blood Coagulation Disorders Blood Platelet Disorders Hemorrhage Hemostatic Disorders Purpura, Thrombocytopenic Thrombocytopathy |
Signs and Symptoms Antibodies Thrombocytopenia Hemorrhagic Disorders Immunoglobulins, Intravenous Thrombocytopenic Purpura, Autoimmune Purpura, Thrombocytopenic, Idiopathic Rho(D) Immune Globulin Immunoglobulins |
Purpura Skin Manifestations Autoimmune Diseases Immunologic Factors Immune System Diseases Hematologic Diseases Blood Coagulation Disorders Blood Platelet Disorders Physiological Effects of Drugs Pharmacologic Actions |
Purpura, Thrombocytopenic Signs and Symptoms Antibodies Thrombocytopenia Hemorrhagic Disorders Immunoglobulins, Intravenous Purpura, Thrombocytopenic, Idiopathic Rho(D) Immune Globulin Immunoglobulins |